Hengrui Pharmaceutical (600276.SH) subsidiary's injectable Ruikang Luzetolatamab was included in the list of breakthrough therapeutic varieties

Zhitongcaijing · 2d ago

Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiary Suzhou Shengdia Biomedical Co., Ltd.'s injectable Ruikang luzetutazumab (injectable SHR-A2009) was included in the list of breakthrough treatment varieties by the Drug Evaluation Center of the China Drug Administration. The drug is intended for treatment with bevacizumab in patients with locally advanced EGFR mutations or metastatic non-squamous non-small cell lung cancer (NSCLC) who have previously failed to be treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI).

According to reports, Recon ruzetolatumab for injection is an antibody-drug conjugate targeting HER3. It can specifically bind to HER3 on the surface of tumor cells, then be endocytosed into cells and transported to lysosomes. Water releases free toxins and kills tumor cells. HER3 expression was found in various solid tumors. Among them, HER3 expression accounted for about 82.7% in NSCLC, and HER3 expression increased after EGFR TKI treatment. Currently, the marketing license application for this project's single drug for non-small cell lung cancer clinical trials has been accepted, and there are no HER3-targeting ADCs approved to treat NSCLC in the world. Up to now, the total R&D investment in projects related to Ruikang Luzetolatamab for injection is about 355 million yuan (unaudited).